Tofacitinib for the Treatment of Refractory Immune-related Colitis From Checkpoint Inhibitor Therapy- TRICK Study
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This is a single-arm pilot study evaluating the efficacy and safety of tofacitinib in cancer
patients with immune-related colitis from immune checkpoint inhibitor (ICI) therapy.